N-[3-(dimethylamino)propyl]-4-[4-fluoro-2-(1-fluoropropan-2-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide | 1332759-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: N-[3-(dimethylamino)propyl]-4-[4-fluoro-2-(1-fluoropropan-2-yloxy)anilino]-5-methylthieno[2,3-d]pyrimidine-6-carboxamide
• CAS: 1332759-94-0
• 化学式: C₂₂H₂₇F₂N₅O₂S
• 分子量: 463.551
• InChiKey: WTCFYBGLEUOJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• METHOD OF INHIBITING HIGH FAT DIET-RELATED CONDITIONS
  申请人：South Australian Health and Medical Research Institute Limited

  公开号：US20190117657A1

  公开（公告）日：2019-04-25

  A method of treating a pre-diabetic subject is disclosed wherein the subject is characterised by having a fasting plasma glucose level from 5.5 mmol/l to 6.9 mmol/l. The method comprises administering to the subject a therapeutically effective amount of at least one mitogen-activated protein kinase-interacting kinase (MNK) inhibitor, wherein said MNK inhibitor reduces the biological activity of MNK1 and/or MNK2. The method may prevent and/or delay progression of pre-diabetes to type 2 diabetes. The method may also prevent progression of pre-diabetes at the impaired fasting glucose (IFG) stage to the impaired glucose tolerance (IGT) stage.